Though many may disagree with me, I think this is a good writeup. Very good indeed,
Many people are here because of GERN's stem cells r/d and most are disappointed because of the exit. If GERN would continue with the original path in the absence of any FDA changes in its current approach in regulating this type of r/d, GERN would have failed the spinal cord injury trial, leading to a total collapse of the company. BTX is approaching the stem cells r/d differently with more emphasis in basic r/d in the US and maybe clinicals overseas (such as Asia, where BTX has a strong connection).
I don't disagree and find this was a fair and well written report. Although, I have been disappointed by the discontinuation of HESC research, if the BTX deal goes ahead as planned my shares in Geron would guarantee that I'll still be invested in HESC through BTX's planned BAC plan and at the same time be invested in Imetelstat. Of course, this deal should have been much better but Geron is certainly not currently negotiating from a position of power.
Franshei, if you study management actions of companies like ACTC and EXEL, you will realize that Geron management certainly lacks foresight and sincerity to serve its shareholders. There are many steps Geron management took were very unwise, exhibiting their lack of foresight. For example, Lawton points out in his article that Geron management really frustrated longs so often that not only they but institutional investors he talked to have no confidence in the management; so much so that the institutional investors want to wait till the share price reaches $3 before they would jump in!! Certainly, Lawton expresses the thoughts of all long-term investors who have been burnt all along. This is NOT something to be proud of on the part of Geron's management!
Also, the mangement got rid of most of the hard working scientists and technicians, while giving themselves fat salaries and bonuses when the company was strapped for cash. Those scientists and technicians, I bet, also were frustrated with Huh-Scarlett and company!
Now, if Geron wants to go all alone with commercialization of Imetelstat and then develop as a company like an Amgen, it doesn't have juice or any body like ACTC's Lanza to swear! Do you think these two bozos can run a company like Amgen? Therefore, I have hardly any doubt that this company will be sold or merged with who knows what (something like BTX?). If these two bozos could sell the entire stem-cell portfolio for just $12-15M only, do you expect them to be capable of getting any hefty merger deal with Imetelstat only? Also, just compare the salaries and remuneration of management personnel and high-ranking technical staff currently, including Kelsey, for such a resaerch company and you will see that there is an improper balance there.
Yes, Robert Lawton is pretty honest in expressing his thoughts and doubts in the article and deserves rare compliments.
Generally true, maine. But, this one should be reviewed with an unbiased mind. Lawton just expresses some optimism after all frustrations we have experienced with Geron management. He still doesn't laud this management when he does state that the institutional investors do not want to jump in until the share price is lifted from the current level to $3. I think he expresses what we all may be thinking; and, therefore, I ignore whether he comes through Seeking Alpha or any such source.